Quarterly ResultMay 13, 2026, 06:52 AM
Aprea Therapeutics Q1 Net Loss $(3.29)M; Cash $46.5M
AI Summary
Aprea Therapeutics reported a net loss of $(3.29) million for the first quarter of 2026, an improvement from $(3.93) million in the prior year. The company's cash and cash equivalents significantly increased to $46.5 million as of March 31, 2026, up from $14.6 million at year-end 2025, primarily driven by recent private placements. This enhanced liquidity is projected to fund the company's operating expenses and capital expenditure requirements into the first quarter of 2028.
Key Highlights
- Net loss for Q1 2026 was $(3,287,917), an improvement from $(3,932,659) in Q1 2025.
- Cash and cash equivalents increased to $46,466,202 as of March 31, 2026.
- Total assets rose to $47,612,387 at March 31, 2026, from $15,933,401 at Dec 31, 2025.
- Research and development expenses decreased to $1,611,167 in Q1 2026 from $2,483,066 YoY.
- Net loss per share improved to $(0.22) in Q1 2026 from $(0.66) in Q1 2025.
- Net cash provided by financing activities was $34,624,149 in Q1 2026.
- Company expects current cash to fund operations into the first quarter of 2028.
- January 2026 private placement generated $5.6 million in gross proceeds.
- March 2026 private placement included 37.17 million pre-funded warrants.